‘Survive To Thrive’ Becomes Mantra In Altered VC Landscape
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal designs and investor demands are changing, venture capitalists find – but major innovations can still win.
You may also be interested in...
Alzheimer’s Player Satori Wades Into Fray With Mystery Technology – And $22 Million
“Year or two” of pre-IND work lies ahead with new amyloid approach, CEO says.
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
With a would-be competitor from Discovery Labs stalled at FDA, approved lung surfactant Curosurf sits at the center of equity, cash tie-up.